GPR52 represents a promising therapeutic target for the treatment of not only HD but also Parkinson’s disease (Russell et al., 2021), schizophrenia, and several other psychiatric disorders (Komatsu et al., 2014). This evidence concerns the gene GPR52 and Huntington disease.